A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing

Xin-Zhu Chen1,2†, Rong Guo3†, Cong Zhao4†, Jing Xu5, Hang Song5, Hua Yu6, Christian Pilarsky7, Firzan Nainu8, Jing-Quan Li2*, Xin-Ke Zhou1* and Jian-Ye Zhang1*

1Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China, 2The First Affiliated Hospital, Hainan Medical University, Haikou, China, 3State Key Laboratory of Medical Molecular Biology, Department of Molecular Biology and Biochemistry, Institute of Basic Medical Sciences, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China, 4Department of Cellular and Molecular Biology, Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Beijing, China, 5Department of Biochemistry and Molecular Biology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China, 6State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China, 7Department of Surgery, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), Erlangen, Germany, 8Faculty of Pharmacy, Hasanuddin University, Makassar, Indonesia

Cancer becomes one of the main causes of human deaths in the world due to the high incidence and mortality rate and produces serious economic burdens. With more and more attention is paid on cancer, its therapies are getting more of a concern. Previous research has shown that the occurrence, progression, and treatment prognosis of malignant tumors are closely related to genetic and gene mutation. CRISPR/Cas9 has emerged as a powerful method for making changes to the genome, which has extensively been applied in various cell lines. Establishing the cell and animal models by CRISPR/Cas9 laid the foundation for the clinical trials which possibly treated the tumor. CRISPR-Cas9-mediated genome editing technology brings a great promise for inhibiting migration, invasion, and even treatment of tumor. However, the potential off-target effect limits its clinical application, and the effective ethical review is necessary. The article reviews the molecular mechanisms of CRISPR/Cas9 and discusses the research and the limitation related to cancer clinical trials.

Keywords: CRISPR/Cas9, gene editing technology, anti-cancer therapy, off-target effect, ethics

INTRODUCTION

The clustered regularly interspaced short palindromic repeats (CRISPR)/-CRISPR-associated nuclease (Cas) system is an acquired defense system to protect organisms from invading viruses and plasmids and is widespread in various bacteria and archaee (Jinek et al., 2012; Wiedenheft et al., 2012; Hsu et al., 2014). CRISPR loci are separated by a CRISPR array, comprising unique spacers consisted of short variable DNA sequences, which are flanked by diverse cas (CRISPR-associated) gene (Makarova et al., 2015; Koonin and Makarova, 2019). Among them, CRISPR is a series of short direct repeats interspersed with short sequences in E. coli that was discovered by Japanese researchers in 1987 (Ishino et al., 1987). The Cas gene encodes the Cas protein components with putative nuclease and helicase domains (Jansen et al., 2002; Haft et al., 2005). The CRISPR-Cas immune response includes three phases: adaptation; pre-CRISPR RNA (pre-crRNA) expression and processing; and interference to protect prokaryotes from succumbing to infection (Wiedenheft et al., 2012; Hille et al., 2018; and Koonin and Makarova, 2019).
The CRISPR/Cas systems are divided into two classes, which are further classified to six types and 33 subtypes that each possess signature cas gene (Makarova et al., 2020). The type II CRISPR/Cas9 system is mainly used in gene editing because of its simplicity, high efficacy, and ease to use (Liu et al., 2017). Cas9 is a large multifunctional protein that has two putative nuclease domains: HNH and RuvC to cleave DNA strands (Nierzwicki et al., 2021; Shams et al., 2021). The CRISPR/Cas9 system contains three core elements: the Cas9 protein, the CRISPR RNA (crRNA), and a trans-activating CRISPR RNA (tracrRNA), of which tracrRNA bears complementarity to the repeat regions of crRNA (Deltcheva et al., 2011). The Cas9 protein associates with a mature dual RNA (tracrRNA:crRNA), as a single-guide RNA (sgRNA) to target DNA cleavage. To interfere with the expression of target genes, Cas9 identifies the viral DNA sequence through a short protospacer adjacent motif (PAM) recognition that was able to select the target DNA among the genome (Sternberg et al., 2014). After the Cas9 protein binds to the target sequence, it results in double-stranded DNA breakings (DSBs) in specific regions of the genome (Frock et al., 2015). DSBs are repaired by different DNA damage repair mechanisms in cells: homology-directed repair (HDR), classical non-homologous end joining (cNHEJ), and microhomology-mediated end joining (MMEJ) (Rassool, 2003; Brinkman et al., 2018; Schep et al., 2021). Various DNA repair pathways might be used to repair each end at a DSB leading to the potential for asymmetric repair (Nambiar et al., 2022) (Figure 1). In clinical practice, these repair methods are used to achieve the purpose of relieving or even curing diseases.

DSBs are generated and repaired at specific positions in CRISPR/Cas9-mediated targeted gene segments, leading to targeted mutations because the repair process is error-prone. Though editing the targeted mutation, CRISPR/Cas9 gene editing has shown tremendous potential in oncology and has attained an encouraging achievement.

**THE RESEARCH OF CRISPR/CAS9 FOR ANTI-CANCER THERAPY**

Cancer is the first or second leading cause of mortality and ranks as an important barrier to increasing life expectancy of the world (Bray et al., 2021; Sung et al., 2021). Tumor formation involves a variety of gene mutations and epigenetic mutations (Podlaha et al., 2012; Huang et al., 2020). Cancer genome sequencing has confirmed that there was a multitude of genes and epigenetic mutations in human tumors (Gerstung et al., 2020). At present, there are various methods to treat tumor, such as conventional...
cancer therapy including operation, chemotherapy and radiotherapy, molecular targeted therapy, immunotherapy, and genetic therapy. Traditional methods pose a significant challenge to patients’ tolerability and adherence due to toxicity (Mun et al., 2018). Molecular targeted drugs, one of the anti-tumor drugs, have gradually replaced traditional chemotherapeutic drugs with their advantages of high targeting and efficacy, which have made revolutionary progress in the treatment of malignant tumors. However, during the clinical application, dramatic but short-lived tumor regressions and expenses limit the benefits (Vanneman and Dranoff., 2012). Tumor immunotherapy refers to the actively or passively tumor-specific responses to suppress cancer, including immune checkpoint blocks (ICBs), adoptive cell transfer (ACT), and tumor-specific vaccines (Zhang and Zhang, 2020). Despite immunotherapy marking the beginning of a new era in cancer, it only works in a subset of cancers and a fraction of patients with cancer respond to immunotherapy (Yang, 2015). Meanwhile, the existence of immune escape makes the effect less than expected.

The gene therapy contains zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the CRISPR/Cas9 system, which knockout, insert, and mutate the targeted gene to treat cancer (Knott and Doudna, 2018). ZFNs and TALENs have been applied in editing targeted gene in the body; however, they are time-consuming and complicated (Gaj et al., 2013). Compared to ZFNs and TALENs, the CRISPR/Cas9 system is the method of choice for gene editing due to its simplicity, practicability, and application diversity. Hence, the CRISPR/Cas9 system is used widely. For tumor and immune cells, CRISPR/Cas9 gene editing is expected to provide a new strategy for tumor therapy.

The Application of CRISPR/Cas9 Technology in Tumor Cells

CRISPR-Cas9 technology is used in tumor cells to overcome cancer. The tumor cell editing mainly has the following methods:

1. Gene knockout is the simplest and most common approach that has tremendous potential in clinical trials, mainly for pathogenic genes. In 2012, it was confirmed that Cas9 could cut programmatically various DNA sites in vitro (Jinek et al., 2012). For example, through gene editing of CCR5 in CD4+ T cells from persons who have been infected with HIV helps to combat HIV infection (Hsu et al., 2014; Tebas et al., 2014; Xu et al., 2019). Similarly, disrupting the intronic erythroid-specific enhancer for the BCL11A gene could increase HbF protein expression to possibly cure sickle-cell anemia (SCD) and β-thalassemia (Basak and Sankaran, 2016);

2. Targeted insertion of DNA fragments helps to correct mutation to restore the normal sequence (Mali et al., 2013). Theodore et al. applied the strategy that inserting large DNA sequences (>1 kb) helps to correct IL2RA mutation in cells from patients with monogenic autoimmune disease (Roth et al., 2018);

3. Translocation of chromosomal fragment was closely associated with tumorigenesis, for instance, modeling cancer-related chromosomal translocations was able to facilitate cancer pathogenesis research (Mani and Chinnaiyan, 2010). Irina et al. have modeled the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblast by CRISPR/Cas9, which benefits researchers to explore the mechanism of the tumorigenic process (Lagutina et al., 2015);

4. Base editing to obtain the point mutation for the purpose of various gene editing steps, such as to monitor and screen (Zhang, 2021). As we all know, the largest class of human pathogenic mutations was the point mutation (also called single nucleotide polymorphism, SNP), so that a new technology was required to change specifically an individual base pair within a vast genome (Landrum et al., 2016; Rees and Liu, 2018). Based on the CRISPR/Cas9 system, David R. Liu’s group developed a CRISPR/Cas9 base editor (BE) technology, also known as cytosine base editors (CBEs), to replace specific base, for instance, convert cytidine (C) to thymine (T) or guanine (G) to adenine (A) (Komor et al., 2016). Later, adenosine base editors (ABEs) were developed to convert an A-T base pair to a G-C base pair (Gaudelli et al., 2017). In short, ABEs and CBEs provide four possible changes to correct point mutations (Rees and Liu, 2018).

The tumor cell models were established to test in vitro therapeutic effects, explore the mechanisms of drug actions, and clarify pathogenesis as well by the CRISPR-Cas9-mediated genome editing technology (Augert et al., 2020). Recently, the research about CRISPR/Cas9 gene editing technology in human cells was popularly increasing (Wang et al., 2014). The Human Genome Project and International HapMap Project showed more comprehensive data and have attracted considerable interest from scientists to explain the relation between gene and disease, especially tumor (Bayarsaikhan et al., 2021). With the involvement of the CRISPR/Cas system in drug discovery, the combination contains the CRISPR/Cas9 system, and stem cells would be applied to simulate at least 75,000 diseases associated with human genetic variants (Ledford, 2019). By revealing the gene–gene interactions to synthetic lethality of genes by the CRISPR system, we could obtain the candidate drug. The researchers exposed myeloid leukemia KBM7 cells to the CRISPR/Cas9 system that carrying a library of more than 70,000 sgRNAs; thus, drug-resistant genes would be identified (Wang et al., 2014). It was not only a complicated process in drug discovery but also time-consuming. Due to the high-screening knockout by the CRISPR/Cas9 system, it was increasing to elucidate the function of gene. Meanwhile, the induced pluripotent stem cells (iPSCs) with unlimited self-renewal capability were able to differentiate into cells of any lineage attract, which owned a value in cell disease modeling (Wang et al., 2017). An immunodeficiency, centromeric region instability, and facial anomalies syndrome (ICF) model was edited efficiently in human-induced pluripotent stem cells (hPSCs) by using the CRISPR system (Horii et al., 2013). Based on the CRISPR/Cas9 system, Faquet et al. introduced mono- and biallelic sequence changes to hPSCs to establish the model with Alzheimer’s disease-causing mutations in...
The Application of CRISPR/Cas9 Technology in Animals

Animal tumor models have laid a foundation for revealing the molecular mechanism of tumorigenesis and development. Animal models were ideal carriers that effectively integrate basic, clinical tumor research, which have been widely used throughout cancer research. The disease animal models played a crucial role in drug development and therapeutic approaches as an in vivo tool. Animal tumor models can be classified into four categories: carcinogen-induced models (CIMs), spontaneous and induced models, genetically engineered models, and transplant models, in which transplant models were divided into orthotopic models, heterotopic tumor models, and primary patient-derived xenografts (PDXs) (Burtin et al., 2020). Gene knockout animal tumor models, referring to genetically engineered models, use the gene knockout method to remove genes to induce tumorigenesis (Takeda et al., 2019). This is an ideal model for understanding the role of a single gene or several genes in tumorigenesis. Compared to other gene editing technologies such as ZFNs and TALENs, CRISPR/Cas9 technology has the advantages of cost, efficiency and timesaving. Scientists have creatively applied the CRISPR system for studying malignant tumors and constructed multiple animal tumor models. Precise gene editing has been successful in various animals, including rat (Li et al., 2013; Wang et al., 2013), goat (Ni et al., 2014), rabbit (Honda et al., 2015; Yuan et al., 2016), dog (Zou et al., 2015), monkey (Chen et al., 2015), pig (Zhou et al., 2015), C. elegans (Friedland et al., 2013), and zebrafish (Hruscha et al., 2013; Varshney et al., 2015) (Table 1).

Table 1

| Animal  | Targeted gene | Mutation or disruption efficiency | Other                                      | Reference                      |
|---------|---------------|----------------------------------|--------------------------------------------|--------------------------------|
| Rat     | Tet1          | 36%                              | Tet1 and Tet2 with biallelic mutations in both genes with an efficiency of 80% | Li et al. (2013); Wang et al. (2013) |
|         | Tet2          | 48%                              |                                             |                                |
|         | Tet3          | 36%                              |                                             |                                |
| Goat    | MSTN          | 32%                              | Potential off-target but no unwanted mutation occurred | Ni et al. (2014) |
|         | MSTN/Prp      | 20%                              |                                             |                                |
|         | MSTN/BLG/PpNp | 4%                               |                                             |                                |
| Rabbit  | Tyrosinase CR2| 3%                               | No off-target mutation                     | Honda et al. (2015)            |
|         | GJA8          | 98.7%                            | —                                           | Yuan et al. (2016)             |
| Dog     | MSTN          | Monoallelic mutation: 22.7%      | Biallelic mutation: 36.4%; no mutation: 40.9% | Zou et al. (2015)              |
| Pig     | TYR           | 49.4%                            | Double homozygous (PAPK2 and PINK1): 38.1%  | Zhou et al. (2015)             |
|         | PAPK2         | 68.7%                            |                                             |                                |
|         | PINK1         | 69.9%                            |                                             |                                |
| Monkey  | DMD (exon 4 and exon 46) | Mosaic mutations: 87% | —                                           | Chen et al. (2015) |
|         | Ppar-γ        | 10%–25%                          | No authentic mutation was detected          | Niu et al. (2014)              |
|         | Rag1          | 23.80%                           |                                             |                                |
|         | NrOb1         | ~20%                             |                                             |                                |
| Zebrafish | bpt1, bpt4, C9t2, and C9t3 | 86%, heritable                      | Mutation rates at potential off-target sites are 1.1–2.5% | Hruscha et al. (2013) |

The CRISPR/Cas9 technology in SSCs did not change the paternal imprinting...
pattern that displayed a great promise to treat diseases (Wu et al., 2015). From the point of view of animal studies, it is more effective for the generation of transgenic animals by CRISPR/Cas9. CRISPR/Cas9 technology is integrated into tumor cell molecular biology research, allowing for accurate and quick editing of genomes, constructing animal tumor models of gene mutation and knockout to promote comprehensive research on tumor-related genes and tumor development. The CRISPR/Cas9 system was applied not only in animals but also in insects (Shirai et al., 2022). The latest research showed that “direct parental” CRISPR (DIPA-CRISPR) was defined as a method in which the RNPs were injected into the hemocoel of females to introduce the hereditary mutation in developing oocytes and successfully applied them in cockroaches and Tribolium castaneum. It is an exciting breakthrough to achieve the gene editing in cockroaches due to the unique reproduction system.

**The Clinical Trial of CRISPR/Cas9 Technology**

The purpose of developing new treatment methods is to achieve the purpose of preventing, alleviating, and even treating diseases. The emergence of CRISPR/Cas9 gene editing technology reflects the urgent need for treating diseases that are currently incurable, such as tumor. Applying this technology to the treatment of human diseases will bring hope to patients. In 2012, 2013, and 2015, CRISPR made the cut “breakthrough of the year,” which achieved great success such as creating a contagious gene to fight malarial infection (Hammond et al., 2016; Macias et al., 2020).

Tumor treatment is complicated and frequently accompanied by immune escape, so that it is necessary to overcome the immune escape as a crucial treatment strategy. Chimeric antigen receptor T (CAR-T) cells have been provided with tumor cell-specific antigen chimeric domains, which can activate T cells and achieve killing effect on tumor cells (Hu et al., 2021). The signaling pathway—programmed death receptor 1 (PD-1)/programmed cell death ligand 1 (PD-L1)—led to melanoma, non-small cell lung cancer (NSCLC), colorectal cancers (CRCs), bladder cancer, and renal-cell cancer if it was activated (Ott et al., 2020; O’Neil et al., 2017; Topalian et al., 2012; Stein et al., 2021; and Yi and Li, 2016). PD-1 was encoded by the PDCD1 gene, which blocked the binding of PD-1 to its receptor PD-L1 to enhance the activation of T cells to fight cancer by improving the IFN-γ expression (Lu et al., 2020; Stadtmauer et al., 2020). Combining CRISPR/Cas9 with CAR-T cells and PD-1, the editing PDCD1 gene in T cells was an ideal method to cure cancer (Xu et al., 2022). In 2016, the first human phase I clinical trial of CRISPR was conducted in China to therapy metastatic NSCLC patients who did not respond to chemotherapy, radiotherapy, and other therapies (Lacey and Fraietta, 2020; Lu et al., 2020). Similarly, knocking TRAC region and CD52 gene in CAR-T cells by CRISPR/Cas9 avoided the host immune-mediated rejection for relapsed/refractory acute lymphoblastic leukemia (t/r ALL) (Hu et al., 2021). Su et al. have confirmed that targeting PD-1 in the T cells from patient with melanoma and gastric
TABLE 2 | Clinical trials of the CRISPR/Cas9 system.

| Target     | Therapy                                      | Clinicaltrials.gov number | Reference                      |
|------------|----------------------------------------------|----------------------------|--------------------------------|
| CCR5       | HIV                                         | NCT00842634                | Tebas et al. (2014)            |
| BCL11A     | Sickle-cell anemia (SCD) and β-thalassemia    | NCT03184135                | Xu et al. (2019)               |
| PDCD1 (PD-1) | Non-small-cell lung cancer (NSCLC)       | NCT03745287                | Basak and Sankaran, (2016)     |
|            | Advanced refractory myeloma and metastatic sarcoma | NCT03665678 | Frangoul et al. (2021)        |
|            | Relapsed/refractory acute lymphoblastic leukemia (r/r ALL) | NCT02799856 | Lu et al. (2020)              |
|            | Mesothelin-positive solid tumors            | NCT0399448                | Stadtmueller et al. (2020)    |
|            | Metastatic colorectal cancer                | NCT04227015               | Hu et al. (2021)               |
|            | Bladder cancer                              | NCT03545815               | Wang et al. (2021)             |
|            | Prostate cancer                             | NCT03174405               | Stein et al. (2021)            |
|            | Metastatic renal cell carcinoma             | NCT02867345               | Yi and Li, (2016)             |
| E6 and E7  | HPV                                         | NCT02865913                |                                |
| RPE65      | Leber’s congenital amaurosis type 10 (LCA10) | NCT02867332 |                                |
| TTR        | Transthyretin amyloidosis (ATTR amyloidosis) | NCT03057912 | Khairkhah et al. (2022)       |
|            |                                              | NCT03057912                |                                |
|            |                                              | NCT03672479                | Maeder et al. (2019)           |
|            |                                              | NCT04601051                | Gillmore et al. (2021)         |

cancer resulted in the improvement of cytotoxicity of T cells, and the tumor cells were killed (Su et al., 2016). The successful practice of this gene therapy has laid the foundation for the clinical trial of CRISPR/Cas9 gene editing technology to inhibit tumor metastasis in human.

There are various genetic mutations in the process of tumor evolution such as proto-oncogene and tumor-suppressor gene. More and more mutated genes related to tumors have been identified by genome-sequencing technology. The efficient and specific gene editing function of the CRISPR/Cas9 system provides the possibility to directly target the mutated genes that cause cancer in vivo. As we all know, the epidermal growth factor receptor (EGFR) gene was changed in approximately 10%~15% of NSCLC, which played an essential role in tumor progression (Koo et al., 2017). Currently, EGFR inhibitors are the first-line drugs for curing lung cancer with EGFR mutation (Janne et al., 2022). However, the development of resistance and the efficacy of drugs were limited. It was a need to develop novel tools for EGFR-mutated NSCLC, and CRISPR/Cas9 gene editing technology maybe a promising method to correct cancer-driven mutations for cancer therapy. Experiments have shown that knocking out the EGFR mutant allele (L858R) in H1975 lung cells resulted in dying of cancer cells and decreasing tumor volume. Cervical cancer was related to human papilloma virus (HPV). After targeting E6 and E7 oncogenes, tumor growth was suppressed (Khairkhah et al., 2022). However, safety and specificity of CRISPR/Cas9 need to be optimized before executing in the clinical setting. The nuclear receptor binding SET domain-containing protein 1 (NSD1) was one of the biomarkers to participate in a variety of malignancies, and human hepatocellular carcinoma (HCC) was one of them. Knocking the NSD1 gene in HCC cells led to the function of cell proliferation, migration, and invasion that were suppressed (Zhang et al., 2019b). Targeting the reticulon 4B (Nogo-B), a negative modulator of apoptosis, was able to inhibit the ability of cell proliferation in vitro and tumor growth in vivo (Zhu et al., 2017). Based on the CRISPR/Cas9 system, it was probable to provide individualized targeted therapy, which showed potential in tumor therapy at the gene level and rises a high level.

Meanwhile, the Zhang Feng’s group successfully restored vision in Leber’s congenital amaurosis type 10 (LCA10) in 2019, which showed the feasibility of CRISPR-based gene editing therapy in the treatment of genetic diseases (Maeder et al., 2019) (Table 2).

CHALLENGES OF THE CRISPR/CAS9 SYSTEM

As only a specific nucleic acid sequence of 20 bp was provided by using CRISPR/Cas for gene editing, its construction process was simpler and faster than ZFNs and TALENs, owing to ZFNs and TALENs must depend on the Fok I enzyme to exert. In contrast, the CRISPR technology target design was simpler and efficient, making it an ideal gene editing tool. However, it may also cause “off-target” effects, and the gene sequences should not be edited to result in unpredictable consequences. This made CRISPR more secure when used in vivo because once off-target occurred, it cannot be checked and corrected in a timely manner like in vitro experiments. The new types of Cas9, such as sCas9 and Cpf1, have been developed but cannot completely get rid of the dependence on PAM (Wang et al., 2018). This year, the newest types of Cas9-Cas9TX can inhibit the occurrence of chromosomal structural abnormalities such as chromosomal translocations and large fragment deletions in the process of gene editing and greatly improve the safety of CRISPR/Cas9 gene editing (Yin et al., 2022).

In 2018, “Gene-edited Infant” event brought a lot of controversy to the application of CRISPR at the clinical level, and direct violation of the international scientific consensus that CRISPR/Cas9 technology was not ready or appropriate for making changes to humans that could be passed on through generations until the technology matures and becomes widespread (Kofter, 2019). At this time, how to define whether accepting human beings have the right to choose their own genes in place of future generations, or whether the modified human beings can enjoy the rights of ordinary people will become a problem that needs to be pondered (Zhang et al., 2019a). The effective ethical review is the proper meaning of strengthening the
ethical governance of science and technology. Therefore, it is the top priority to improve the ethical review system for human genome editing activities.

CONCLUDING REMARKS AND FUTURE PERSPECTIVES

In the past decade, CRISPR/Cas9 gene editing technology as a strategy to therapy disease successfully entered preclinical and clinical stages. With the continuous improvement of gene editing tools and the identification of new effective targets for diseases, the clinical translation and application research of gene editing technology has been expanded. Not only in insects and plants, but also in animals and even in humans, the CRISPR/Cas9 gene editing technology proves its powerful utility.

Specific gene mutation improved tumor migration, invasion, and angiogenesis, which could be reversed by targeting editing genome. At present, the in vivo gene-editing based on the CRISPR/Cas system is currently being used for diseases, such as tumor and immune diseases. At present, the clinical programs are being carrying out to verify the effects of CRISPR/Cas9 and have made outstanding achievements. However, the clinical trials have been developed only involving a small number of patients and a limited follow-up, for which the further in-depth research studies are planned (Frangouli et al., 2021). Meanwhile, long-term safety monitoring is needed to confirm the effects and unknown adverse reactions (Frangouli et al., 2021; Gillmore et al., 2021). Developing and optimizing the Cas9-based gene editing should promote the technology forward to therapeutic applications and offer a wide variety of treating strategies for human diseases, especially tumor.

In spite of the application of CRISPR/Cas9, it brings promise for tumor therapy associated with gene mutation; problems such as off-target and ethics need to resolved. Scientists must begin to observe the international consensus and strive to advance society positively by technology (Kofler, 2019). We still have a long way to go until the CRISPR/Cas9 technology is ready to treat cancer maturely.

AUTHOR CONTRIBUTIONS

X-ZC, RG, and CZ wrote the manuscript. JX and HS designed the figures. HY, CP, and FN finished the tables. J-YZ, X-KZ, and J-QL designed and revised the manuscript. All authors have read and approved the final version of the manuscript.

FUNDING

This work was supported by the National Key R&D Program of China (2021YFE0202000), the Finance Science and Technology Project of Hainan Province (ZDYF2021037), the Guangdong Basic and Applied Basic Research Foundation (2020A1515010605), and the Fund of Guangdong Education Department (2021ZDZX2006).

REFERENCES

Augert, A., Mathyraja, H., Ibrahim, A. H., Freie, B., Geuenich, M. J., Cheng, P. F., et al. (2020). MAX Functions as a Tumor Suppresser and Reverses Metabolism in Small Cell Lung Cancer. Cancer Cell 38, 97–114.e7. doi:10.1016/j.ccc.2020.04.016
Basak, A., and Sankaran, V. G. (2016). Regulation of the Fetal Hemoglobin Silencing Factor BCL11A. Ann. N. Y. Acad. Sci. 1368, 25–30. doi:10.1111/nyas.13024
Bayarsaikhan, D., Bayarsaikhan, G., and Lee, B. (2021). Recent Advances in Stem Cells and Gene Editing: Drug Discovery and Therapeutics. Prog. Mol. Biol. Transl. Sci. 181, 231–269. doi:10.1016/bs.pmbts.2021.01.019
Bray, F., Laversanne, M., Weiderpass, E., and Soerjomataram, I. (2021). The Ever-Increasing Importance of Cancer as a Leading Cause of Premature Death Worldwide. Cancer 127, 3029–3030. doi:10.1002/cncr.33587
Brinkman, E. K., Chen, T., de Haas, M., Holland, H. A., Akhtar, W., and van Steensel, B. (2018). Kinetics and Fidelity of the Repair of Cas9-Induced Double-Strand DNA Breaks. Mol. Cell 70 (5), 801–813.e6. doi:10.1016/j.molcel.2018.04.016
Burtin, F., Mullins, C. S., and Linnebacher, M. (2020). Mouse Models of Colorectal Cancer: Past, Present and Future Perspectives. World J. Gastroenterol. 26, 1394–1426. doi:10.3748/wjg.v26.i13.1394
Chen, Y., Zheng, Y., Kang, Y., Yang, W., Niu, Y., Guo, X., et al. (2015). Functional Disruption of the Dystrophin Gene in Rhesus Monkey Using CRISPR/Cas9. Hum. Mol. Genet. 24, 3764–3774. doi:10.1093/hmg/ddv120
Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., et al. (2011). CRISPR RNA Maturation by Trans-encoded Small RNA and Host Factor RNase III. Nature 471, 602–607. doi:10.1038/nature09886
Drost, J., van Jaarsveld, R. H., Ponsioen, B., Zimberlin, C., van Boxtel, R., Buijs, A., et al. (2015). Sequential Cancer Mutations in Cultured Human Intestinal Stem Cells. Nature 521, 43–47. doi:10.1038/nature14415
Frangouli, H., Alshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., et al. (2021). CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. N. Engl. J. Med. 384, 252–260. doi:10.1056/NEJMoA2031054
Friedland, A. E., Tzur, Y. B., Esvelt, K. M., Colaiácovo, M. P., Church, G. M., and Calarco, J. A. (2013). Heritable Genome Editing in C. elegans via a CRISPR-Cas9 System. Nat. Methods 10, 741–743. doi:10.1038/nmeth.2532
Frock, R. L., Hu, J., Meyers, R. M., Ho, Y. J., Kii, E., and Alt, F. W. (2015). Genome-wide Detection of DNA Double-Stranded Breaks Induced by Engineered Nucleases. Nat. Biotechnol. 33, 179–186. doi:10.1038/nbt.3101
Gaj, T., Gersbach, C. A., and Barbas, C. F., 3rd. (2013). ZFN, TALEN, and CRISPR/Cas-based Methods for Genome Engineering. Trends Biotechnol. 31, 397–405. doi:10.1016/j.tibtech.2013.04.004
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., et al. (2017). Programmable Base Editing of A* to G* in Genomic DNA without DNA Cleavage. Nature 551, 464–471. doi:10.1038/nature23464
Gerstung, M., Joly, C., Leschinger, I., Dentro, S. C., Gonzalez, S., Rosebrock, D., et al. (2020). The Evolutionary History of 2,658 Cancers. Nature 578, 122–128. doi:10.1038/s41586-019-1907-7
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., et al. (2021). CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N. Engl. J. Med. 385, 493–502. doi:10.1056/NEJMoA2107454
Hafi, D. H., Selengut, J., Morgedin, E. F., and Nelson, K. E. (2005). A Guild of Subtypes Exist in Prokaryotic Genomes. PLoS Comput. Biol. 1 (6), e60. doi:10.1371/journal.pcbi.0010060
Hammond, A., Galizi, R., Kyrou, K., Simoni, A., Siniscalchi, C., Katsanos, D., et al. (2016). A CRISPR-Cas9 Gene Drive System Targeting Female Reproduction in the Malaria Mosquito Vector Anopheles gambiae. Nat. Biotechnol. 34, 78–83. doi:10.1038/nbt.3439
Hashimoto, M., and Takemoto, T. (2015). Electroporation Enables the Efficient mRNA Delivery into the Mouse Zygotes and Facilitates CRISPR/Cas9-based Genome Editing. Sci. Rep. 5, 11315. doi:10.1038/srep11315

Hille, F., Richter, H., Wong, S. P., Bratovic, M., Ressel, S., and Charpentier, E. (2018). The Biology of CRISPR-Cas: Backward and Forward. Cell 172, 1239–1259. doi:10.1016/j.cell.2017.11.032

Honda, A., Hirose, M., Sankai, T., Yasmin, L., Yuzawa, K., Honsho, K., et al. (2015). Single-step Generation of Rabbits Carrying a Targeted Allele of the Tyrosinase Gene Using CRISPR/Cas9. Exp. Anim. 64, 31–37. doi:10.1538/expanim.14-0034

Horii, T., Tamura, D., Morita, S., Kimura, M., and Hatada, I. (2013). Generation of an ICF Syndrome Model by Efficient Genome Editing of Human Induced Pluripotent Stem Cells Using the CRISPR System. Int. J. Mol. Sci. 14, 19774–19781. doi:10.3390/ijms141019774

Hruscha, A., Krawitz, P., Rechenberg, A., Heinrich, V., Hecht, J., Haass, C., Koonin, E. V., and Makarova, K. S. (2019). Origins and Evolution of CRISPR-Cas Systems. Mol. Biol. Evol. 36, 2693–2718. doi:10.1093/molbev/msz210

Hu, Y., Zhou, Y., Zhang, M., Ge, W., Li, Y., Yang, L., et al. (2021). CRISPR/Cas9–RNA Delivery into the Mouse Zygotes and Facilitates CRISPR/Cas9-based GeneEditing. mrcgenetools.org

Jänne, P. A., Bai, C., Su, W. C., Johnson, M. L., Hayashi, H., Nishio, M., et al. (2019). Metallomic Analysis of the Phosphorylation Status of the EGFR in Human Lung Cancer Cells Using a Sensitive, Label-Free Mass Spectrometry-Based Assay. Mol. Syst. Biol. 15, 935. doi:10.15252/msb.20197532

Koo, T., Yoon, A. R., Cho, H. Y., Bae, S., Yun, C. O., and Kim, J. S. (2017). CRISPR-Cas9 for Genome Editing. Trends Mol. Med. 23, 174–186. doi:10.1016/j.molmed.2016.07.008

Ko, S. B., et al. (2019). Origins and Evolution of CRISPR-Cas Systems. Philos. Trans. R. Soc. Lond B Biol. Sci. 374, 20180087. doi:10.1098/rstb.2018.0087

Lacey, S. F., and Fraiotta, J. A. (2020). First Trial of CRISPR-Edited T Cells in Lung Cancer. Trends Mol. Med. 26, 713–715. doi:10.1016/j.molmed.2020.06.001

Lagutina, I. V., Valentine, V., Picchioe, F., Harwood, F., Valentine, M. B., Villarrejo-Bakells, B., et al. (2015). Modeling of the Human Alveslar Rhabdomyosarcoma Pax3-Foxo1 Chromosome Translocation in Mouse Myoblasts Using CRISPR-Cas9 Nuclease. PLoS Genet. 11, e1005495. doi:10.1371/journal.pgen.1005495

Landrum, M. J., Lee, J. M., Benson, M., Brown, G., Chao, C., Chitipiralla, S., et al. (2016). ClinVar: Public Archive of Interpretations of Clinically Relevant Variants. Nucleic Acids Res. 44, D862–D868. doi:10.1093/nar/gkv1222

Ledford, H. (2019). Super-precise New CRISPR Tool Could Tackle a Plethora of Genetic Diseases. Nature 574, 464–465. doi:10.1038/d41556-019-03164-5

Li, W., Teng, F., Li, T., and Zhou, Q. (2013). Simultaneous Generation and Germline Transmission of Multiple Gene Mutations in Rat Using CRISPR-Cas Systems. Nat. Biotechnol. 31, 684–686. doi:10.1038/nbt.2652

Liu, C., Zhang, L., Liu, H., and Cheng, K. (2017). Delivery Strategies of the CRISPR-Cas9 Gene-Editing System for Therapeutic Applications. J. Control Release 266, 17–26. doi:10.1016/j.jconrel.2017.09.012

Liu, Y., Zeng, Y., Liu, L., Zhuang, C., Fu, X., Huang, W., et al. (2014). Synthesizing and Gate Genetic Circuits Based on CRISPR-Cas9 for Identification of Bladder Cancer Cells. Nat. Commun. 5, 3393. doi:10.1038/ncomms3393

Lu, Y., Xue, J., Deng, T., Zhou, X., Yu, K., Deng, L., et al. (2020). Safety and Feasibility of CRISPR-Edited T Cells in Patients with Refractory Non-small cell Lung Cancer. Nat. Med. 26, 732–740. doi:10.1038/s41591-020-0840-5

Macias, V. M., McKeand, S., Chaverra-Rodriguez, D., Hughes, G. L., Fazekas, A., Pujhari, S., et al. (2020). Cas9-Mediated Gene-Editing in the Malaria Mosquito Anopheles stephensi by Remot Control. G3 (Bethesda) 10, 1353–1360. doi:10.1534/g3.120.011133

Maeder, M. L., Stefanidakis, M., Wilson, C. J., Baral, R., Carrera, L. A., Bounoutas, G. S., et al. (2019). Development of a Gene-Editing Approach to Restore Vision Loss in Leber Congenital Amaurosis Type 10. Nat. Med. 25, 229–233. doi:10.1038/s41591-019-0327-9

Nambiar, T. S., Baudrier, L., Billon, P., and Ciccia, A. (2022). CRISPR-based Allosteric Mechanism in CRISPR-Cas9. WIREs Comput. Mol. Sci. 11, e1503. doi:10.1002/wcms.1503

Neil, B. H., Wallmark, J. M., Lorente, D., Elez, E., Raimbourg, J., Gomez-Roca, C., et al. (2019). Development of a Gene-Editing Approach to Restore Vision in Rhabdomyosarcoma Pax3-Foxo1 Chromosome Translocation in Mouse Myoblasts Using CRISPR-Cas9 Nuclease. PLoS Genet. 11, e1005495. doi:10.1371/journal.pgen.1005495

O’Neil, B. H., Wallmark, J. M., Lorent, D., Elez, E., Raimbourg, J., Gomez-Roca, C., et al. (2017). Safety and Antitumor Activity of the Anti-PD-1 Antibody Pembrolizumab in Patients with Advanced Colorectal Carcinoma. PLoS One 12, e0189848. doi:10.1371/journal.pone.0189848
Zou, Q., Wang, X., Liu, Y., Ouyang, Z., Long, H., Wei, S., et al. (2015). Generation of Gene-Target Dogs Using CRISPR/Cas9 System. J. Mol. Cell Biol. 7, 580–583. doi:10.1093/jmcb/mjv061

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chen, Guo, Zhao, Xu, Song, Yu, Pilarsky, Nainu, Li, Zhou and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.